J2779 Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Billable / valid for submission HCPCS Release 2026Q3

Short description: Inj, susvimo 0.1 mg

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg	yes

J2700 Injection, oxacillin sodium, up to 250 mg
J2704 Injection, propofol, 10 mg
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg
J2711 Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg
J2720 Injection, protamine sulfate, per 10 mg
J2724 Injection, protein c concentrate, intravenous, human, 10 iu
J2725 Injection, protirelin, per 250 mcg
J2730 Injection, pralidoxime chloride, up to 1 gm
J2760 Injection, phentolamine mesylate, up to 5 mg
J2765 Injection, metoclopramide hcl, up to 10 mg
J2770 Injection, quinupristin/dalfopristin, 500 mg (150/350)
J2777 Injection, faricimab-svoa, 0.1 mg
J2778 Injection, ranibizumab, 0.1 mg
J2781 Injection, pegcetacoplan, intravitreal, 1 mg
J2782 Injection, avacincaptad pegol, 0.1 mg
J2783 Injection, rasburicase, 0.5 mg
J2785 Injection, regadenoson, 0.1 mg
J2786 Injection, reslizumab, 1 mg
J2787 Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml
J2788 Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.)